Tags

Type your tag names separated by a space and hit enter

The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease.
Dement Geriatr Cogn Dis Extra 2011; 1(1):150-62DG

Abstract

BACKGROUND

Vascular risk factors (VRF) may influence response to rivastigmine in Alzheimer's disease (AD).

METHODS

AD patients who participated in a randomized, double-blind, placebo-controlled trial of rivastigmine patch and capsule treatment were stratified by baseline VRF status. Treatment response was evaluated using the AD Assessment Scale-cognitive subscale (ADAS-cog), AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale.

RESULTS

ADAS-cog scores significantly improved in all rivastigmine-treated patients (p < 0.05 vs. placebo), except 9.5 mg/24 h patch-treated patients with VRF, and were significantly affected by VRF status in the study population as a whole. Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF. The ADCS-CGIC significantly improved in capsule-treated patients with, and patch-treated patients without VRF. Although non-significant, patients without VRF showed an apparent faster rate of placebo decline.

CONCLUSION

VRF may influence AD progression and response to rivastigmine.

Authors+Show Affiliations

Department of Neurology, Indiana University School of Medicine, Indianapolis, Ind., USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22163241

Citation

Farlow, M R., et al. "The Effect of Vascular Risk Factors On the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease." Dementia and Geriatric Cognitive Disorders Extra, vol. 1, no. 1, 2011, pp. 150-62.
Farlow MR, Doraiswamy PM, Meng X, et al. The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease. Dement Geriatr Cogn Dis Extra. 2011;1(1):150-62.
Farlow, M. R., Doraiswamy, P. M., Meng, X., Cooke, K., & Somogyi, M. (2011). The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders Extra, 1(1), pp. 150-62. doi:10.1159/000328745.
Farlow MR, et al. The Effect of Vascular Risk Factors On the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer's Disease. Dement Geriatr Cogn Dis Extra. 2011;1(1):150-62. PubMed PMID: 22163241.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of vascular risk factors on the efficacy of rivastigmine patch and capsule treatment in Alzheimer's disease. AU - Farlow,M R, AU - Doraiswamy,P M, AU - Meng,X, AU - Cooke,K, AU - Somogyi,M, Y1 - 2011/06/24/ PY - 2011/12/14/entrez PY - 2011/12/14/pubmed PY - 2011/12/14/medline KW - Alzheimer's disease KW - Efficacy KW - Rivastigmine KW - Transdermal patch KW - Vascular risk factors SP - 150 EP - 62 JF - Dementia and geriatric cognitive disorders extra JO - Dement Geriatr Cogn Dis Extra VL - 1 IS - 1 N2 - BACKGROUND: Vascular risk factors (VRF) may influence response to rivastigmine in Alzheimer's disease (AD). METHODS: AD patients who participated in a randomized, double-blind, placebo-controlled trial of rivastigmine patch and capsule treatment were stratified by baseline VRF status. Treatment response was evaluated using the AD Assessment Scale-cognitive subscale (ADAS-cog), AD Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and the AD Cooperative Study-Activities of Daily Living (ADCS-ADL) scale. RESULTS: ADAS-cog scores significantly improved in all rivastigmine-treated patients (p < 0.05 vs. placebo), except 9.5 mg/24 h patch-treated patients with VRF, and were significantly affected by VRF status in the study population as a whole. Significant benefits were seen on the ADCS-ADL in 9.5 mg/24 h patch- and capsule-treated patients with, but not without, VRF. The ADCS-CGIC significantly improved in capsule-treated patients with, and patch-treated patients without VRF. Although non-significant, patients without VRF showed an apparent faster rate of placebo decline. CONCLUSION: VRF may influence AD progression and response to rivastigmine. SN - 1664-5464 UR - https://www.unboundmedicine.com/medline/citation/22163241/The_effect_of_vascular_risk_factors_on_the_efficacy_of_rivastigmine_patch_and_capsule_treatment_in_Alzheimer's_disease_ L2 - https://www.karger.com?DOI=10.1159/000328745 DB - PRIME DP - Unbound Medicine ER -